Biocon’s Mazumdar-Shaw began investing in biologics in the late 90s, when it was just another buzz word. As Biocon did not have too many products to show, its valuation did not go past $1 billion for …
Biocon’s biologics portfolio comes into its own
Biocon’s biologics portfolio comes into its own
Leave a reply